Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veterans

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.

International Indications

International Indications Hyperbaric Oxygen Therapy has been used for the better part of two centuries. Globally, HBOT is used to extend life by augmenting the treatment of over 100 indications. Hyperbaric Oxygen Therapy involves breathing 100% oxygen in a pressurized...